SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System

XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System

The Next Step in BTK Efficacy.

XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System is clinically proven for primary stenting of focal and long lesions and is engineered for outstanding performance.1,2

Advancing BTK efficacy

Clinically Proven

  • Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.3,4
Xience Prime BTK Pre-procedure

Pre-procedure4

Xience Prime BTK Post-procedure

           Post-procedure4

Xience Prime BTK 12 Months Post-procedure

    12 months post-procedure4

Advancing BTK Efficacy

Engineered for outstanding performance

  • Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility5
  • Coating technology for reliable expansion and controlled Everolimus drug release
  • Innovative delivery system for excellent deliverability and confident deployment
Xience Prime BTK Engineering

Ordering Information

XIENCE Prime™ BTK Peripheral Stent System
Stock Number
Stent Diameter (mm)Stent Length (mm)Nominbal Pressure (ATM)
RBP (ATM)Max Stent Expansion Diameter (mm)
1012646-282.5288183.25
1012646-382.5388183.25
1012648-283.02810183.75
1012648-383.03810183.75
1012649-283.52810184.5
1012649-383.53810184.5
1012650-284.02810184.5
1012650-384.03810184.5

 

 

References

  1. Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.
  2. Bosier, M et al.Outcome of a drug eluted stent in longer below the knee lesions in patients with critical limb ischemia: J Vascular Surgery 2017;58(1):49-54
  3. M. Bosiers, DESTINY, VEITH 2010
  4. M. Bosiers, LINC 2011
  5. Tests and data on file at Abbott

MAT-2115185 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0